Cargando…

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and has an exceedingly low median overall survival of only 15 months. Current standard-of-care for GBM consists of gross total surgical resection followed by radiation with concurrent and adjuvant chemotherapy. Temozolomid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Neha, Miner, Alexandra, Hennis, Lauren, Mittal, Sandeep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	OAE Publishing Inc. 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319838/ https://www.ncbi.nlm.nih.gov/pubmed/34337348 http://dx.doi.org/10.20517/cdr.2020.79

Ejemplares similares

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
por: JIAPAER, Shabierjiang, et al.
Publicado: (2018)

Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil
por: Almeida Lima, Karoline, et al.
Publicado: (2023)

Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance
por: Tsai, Yu-Ling, et al.
Publicado: (2020)

Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas
por: Wang, Chun, et al.
Publicado: (2023)

An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?
por: Teraiya, Milan, et al.
Publicado: (2023)

Strategies of temozolomide in future glioblastoma treatment
por: Lee, Chooi Yeng
Publicado: (2017)

Dissecting the mechanism of temozolomide resistance and its association with the regulatory roles of intracellular reactive oxygen species in glioblastoma
por: Chien, Chia-Hung, et al.
Publicado: (2021)

Intracellular Redox-Balance Involvement in Temozolomide Resistance-Related Molecular Mechanisms in Glioblastoma
por: Lo Dico, Alessia, et al.
Publicado: (2019)

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma—A Critical Review
por: Komotar, Ricardo J., et al.
Publicado: (2008)

Considering the Experimental Use of Temozolomide in Glioblastoma Research
por: Herbener, Verena J., et al.
Publicado: (2020)

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
por: Strobel, Hannah, et al.
Publicado: (2019)

Relation between autophagy and the resistence of glioblastoma cells to temozolomide
por: Carmo, Anália, et al.
Publicado: (2010)

Integrins and p53 pathways in glioblastoma resistance to temozolomide
por: Martin, Sophie, et al.
Publicado: (2012)

Metformin treatment reduces temozolomide resistance of glioblastoma cells
por: Yang, Seung Ho, et al.
Publicado: (2016)

Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
por: Thomas, Reena P, et al.
Publicado: (2012)

Obstacles to Glioblastoma Treatment Two Decades after Temozolomide
por: Cruz, João Victor Roza, et al.
Publicado: (2022)

Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment
por: Iturrioz-Rodríguez, Nerea, et al.
Publicado: (2023)

Gossypol Suppresses Growth of Temozolomide-Resistant Glioblastoma Tumor Spheres
por: Kim, Hee Yeon, et al.
Publicado: (2019)

Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin
por: Feng, Shao-Wei, et al.
Publicado: (2022)

Coixendide efficacy in combination with temozolomide in glioblastoma and transcriptome analysis of the mechanism
por: Zhao, Zhenran, et al.
Publicado: (2023)

TRANSLATIONAL RESEARCH-03 MULTIPLE MECHANISMS MODULATE TEMOZOLOMIDE RESISTANCE AND ARE POTENTIAL TARGETS FOR GLIOBLASTOMA THERAPY.
por: Kitange, Gaspar, et al.
Publicado: (2023)

Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma
por: Rabé, Marion, et al.
Publicado: (2020)

Characterization of EGFR-reprogrammable temozolomide-resistant cells in a model of glioblastoma
por: Gong, Lingli, et al.
Publicado: (2022)

SPDR-05 PARP INHIBITORS RESTORE TEMOZOLOMIDE SENSITIVITY IN MSH6-DEFICIENT TEMOZOLOMIDE-RESISTANT GLIOBLASTOMA CELLS
por: Higuchi, Fumi, et al.
Publicado: (2019)

Accelerated hyperfractionation plus temozolomide in glioblastoma
por: Kaul, David, et al.
Publicado: (2016)

Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
por: Saha, Dipongkor, et al.
Publicado: (2020)

MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review
por: Brandner, Sebastian, et al.
Publicado: (2021)

Serum-derived extracellular vesicles facilitate temozolomide resistance in glioblastoma through a HOTAIR-dependent mechanism
por: Wang, Xiaosong, et al.
Publicado: (2022)

Celecoxib reverses the glioblastoma chemo-resistance to temozolomide through mitochondrial metabolism
por: Yin, Delong, et al.
Publicado: (2021)

Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells
por: Zhao, Kai, et al.
Publicado: (2021)

ATP7B expression in human glioblastoma is related to temozolomide resistance
por: Moinuddin, F.M., et al.
Publicado: (2017)

Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma
por: Yin, Jianxing, et al.
Publicado: (2019)

LAPTM5–CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance
por: Berberich, Anne, et al.
Publicado: (2020)

Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death
por: YAMAMOTO, Yutaro, et al.
Publicado: (2018)

Updated systematic review and meta-analysis of extended adjuvant temozolomide in patients with newly diagnosed glioblastoma
por: Gupta, Tejpal, et al.
Publicado: (2023)

Interplay of m(6)A and histone modifications contributes to temozolomide resistance in glioblastoma
por: Li, Fuxi, et al.
Publicado: (2021)

Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models
por: Valtorta, Silvia, et al.
Publicado: (2017)

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
por: Chen, Xiaoyue, et al.
Publicado: (2018)

GENETIC SCREENING REVEALS DEPENDENCY ON FEN1 TO RESIST TEMOZOLOMIDE IN TREATMENT-RESISTANT GLIOBLASTOMA STEM CELLS
por: Brakel, Benjamin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_eccnsfsekc3e2bbclalfkavi6k